IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Clinical trial NCT05958121 · RECRUITING

Trial details

NCT number: NCT05958121
Sponsor: Immatics Biotechnologies GmbH
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Cancer Recurrent Cancer Solid Tumor, Adult Cancer

Start date: 2023-08-09
Primary completion: 2027-09-01
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.